Sökning: onr:"swepub:oai:lup.lub.lu.se:6fd08d0f-4331-473d-a792-53d80b44db15" >
Treatment of severe...
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
-
Borel-Derlon, A. (författare)
-
Federici, A. B. (författare)
-
Roussel-Robert, V. (författare)
-
visa fler...
-
Goudemand, J. (författare)
-
Lee, C. A. (författare)
-
Scharrer, I. (författare)
-
Rothschild, C. (författare)
-
- Berntorp, Erik (författare)
- Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups
-
Henriet, C. (författare)
-
Tellier, Z. (författare)
-
Bridey, F. (författare)
-
Mannucci, P. M. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- Engelska.
-
Ingår i: Journal of Thrombosis and Haemostasis. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 5:6, s. 1115-1124
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of two comparable protocols conducted prospectively in 5 European and 12 French centers. Methods and results: Fifty patients with clinically severe VWD (72% had VWF ristocetin cofactor activity less than 10 IU dL(-1) and 46% had FVIII < 20 IU dL(-1)) were treated with the concentrate as the only therapy, except for clinical situations requiring a priming dose of FVIII to rapidly correct an intrinsic coagulation defect. A total of 139 spontaneous bleeding episodes were treated; only 53 (38%) needed a concomitant FVIII dose. Outcome was excellent or good in 89% of the episodes. Forty-four patients underwent 108 surgical or invasive procedures. Outcome was excellent or good in 95 scheduled procedures (only VWF was infused) and 13 emergency procedures (a priming FVIII dose was co-administered with the first VWF infusion). There were no thrombotic complications and none of the 18 patients with type 3 VWD developed anti-VWF or anti-FVIII antibodies. Conclusions. This concentrate safely and effectively provides hemostasis in patients with clinically severe VWD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- von Willebrand disease
- von Willebrand factor
- concentrate
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Borel-Derlon, A.
-
Federici, A. B.
-
Roussel-Robert, ...
-
Goudemand, J.
-
Lee, C. A.
-
Scharrer, I.
-
visa fler...
-
Rothschild, C.
-
Berntorp, Erik
-
Henriet, C.
-
Tellier, Z.
-
Bridey, F.
-
Mannucci, P. M.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of Throm ...
- Av lärosätet
-
Lunds universitet